Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America

Clinical Infectious Diseases

Volumn 50, Issue 3, 2010, Pages 291-322

  Perfect, John R ^a   Dismukes, William E ^b   Dromer, Francoise ⁱ   Goldman, David L ^c   Graybill, John R ^d   Hamill, Richard J ^e   Harrison, Thomas S ^l   Larsen, Robert A ^f   Lortholary, Olivier ^i,j   Nguyen, Minh Hong ^g   Pappas, Peter G ^b   Powderly, William G ^k   Singh, Nina ^h   Sobel, Jack D ^h   Sorrell, Tania C ^m  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^e MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^h WAYNE STATE UNIVERSITY   (United States)

ⁱ INSTITUT PASTEUR   (France)

^j UNIVERSITÉ PARIS DESCARTES   (France)

^k UNIVERSITY COLLEGE DUBLIN   (Ireland)

^l ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^m UNIVERSITY OF SYDNEY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CORTICOSTEROID; DEXAMETHASONE; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MANNITOL; NEW DRUG; POLYENE; POSACONAZOLE; PREDNISONE; VORICONAZOLE;

CEREBROSPINAL FLUID PRESSURE; CHILD CARE; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS; DRUG FORMULATION; GRAFT RECIPIENT; HEALTH CARE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INTRACRANIAL HYPERTENSION; LUNG INFECTION; MENINGOENCEPHALITIS; MORBIDITY; MORTALITY; MYCOSIS; NEPHROTOXICITY; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT;

ANTIFUNGAL AGENTS; CASE MANAGEMENT; CHILD; CHILD, PRESCHOOL; CRYPTOCOCCOSIS; FEMALE; HUMANS; INTRACRANIAL HYPERTENSION; PREGNANCY; UNITED STATES;

EID: 75749092958     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/649858     Document Type: Review

References (191)

1. 1. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000;30:710-718. (Pubitemid 30736975)
2. Shoham S, Cover C, Donegan N, et al. Cryptococcus neoformans meningitis at 2 hospitals in Washington, D.C.: adherence of health care providers to published practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2005;40:477-479.
3. Dromer F, Bernede-Bauduin C, Guillemot D, et al. Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS ONE 2008; 3:e2870.
4. Kwon-Chung KJ, Boekhout T, Fell JW, et al. Proposal to conserve the name Cryptococcus gattii against C. hondurianus and C. bacillisporus (Basidiomycota, Hymenomycetes, Tremellomycetidae). Taxon 2002;51:804-806.
5. Kidd SE, Hagen F, Tscharke RL, et al. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci U S A 2004; 101:17258-17263.
6. Mirza SA, Phelan M., Rimland D, et al. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis 2003; 36:789-794.
7. Chen SC. Cryptococcosis in Australasia and the treatment of cryptococcal and other fungal infections with liposomal amphotericin B. J Antimicrob Chemother 2002;49(Suppl 1):57-61.
8. 8. van Elden LJ, Walenkamp AM, Lipovsky MM, et al. Declining number of patients with cryptococcosis in the Netherlands in the era of highly active antiretroviral therapy. AIDS 2000; 14:2787-2788. (Pubitemid 32118732)
9. Dromer F, Mathoulin S, Dupont B, et al. Epidemiology of cryptococcosis in France: a 9-year survey (1985-1993). French Cryptococcosis Study Group. Clin Infect Dis 1996;23:82-90.
10. Hakim JG, Gangaidzo IT, Heyderman RS, et al. Impact of HIV infection on meningitis in Harare, Zimbabwe: a prospective study of 406 predominantly adult patients. AIDS 2000; 14:1401-1407.
11. Park BJ, Wannemuehler KA, Marston BJ, et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009;23:525-530.
12. 12. Nath DS, Kandaswamy R, Gruessner R, et al. Fungal infections in transplant recipients receiving alemtuzumab. Transplant Proc 2005; 37:934-936. (Pubitemid 40590748)
13. Hage CA, Wood KL, Winer-Muram HT, et al. Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy. Chest 2003; 124:2395-2397.
14. Dromer F, Mathoulin-Pelissier S, Launay O, et al. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med 2007;4:e21.
15. 15. Lortholary O, Poizat G, Zeller V, et al. Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS 2006;20:2183-2191. (Pubitemid 44684709)
16. French N, Gray K, Watera C, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 2002;16:1031-1038.
17. Chayakulkeeree M, Perfect JR. Cryptococcosis. Infect Dis Clin North Am 2006;20:507-544, v-vi.
18. 18. Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005; 56:745-755. (Pubitemid 41487778)
19. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003;36:1122-1131.
20. 20. Leenders AC, Reiss P, Portegies P, et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997;11:1463-1471. (Pubitemid 27421177)
21. 21. Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004;363:1764-1767. (Pubitemid 38698379)
22. Fraser JA, Giles SS, Wenink EC, et al. Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak. Nature 2005; 437:1360-1364.
23. Canadian Task Force on the Periodic Health Examination. The periodic health examination. Can Med Assoc J 1979;121:1193-1254.
24. Field MJ, Lohr KN. Institute of Medicine Committee to Advise the Public Health Service on Clinical Practice Guidelines, clinical practice guidelines: directions for a new program. Washington, DC: National Academy Press, 1990.
25. 25. Bicanic T, Meintjes G, Wood R, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviralnaive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007;45:76-80. (Pubitemid 46984619)
26. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992;326:83-89.
27. van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997;337:15-21.
28. Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med 1979;301:126-131.
29. 29. Dismukes WE, Cloud G, Gallis HA, et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 1987;317:334-341. (Pubitemid 17118707)
30. 30. Bicanic T, Wood R, Meintjes G, et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis 2008;47:123-130. (Pubitemid 351920599)
31. 31. Sharkey PK, Graybill JR, Johnson ES, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996; 22: 315-321. (Pubitemid 26056161)
32. Baddour LM, Perfect JR, Ostrosky-Zeichner L. Successful use of amphotericin B lipid complex in the treatment of cryptococcosis. Clin Infect Dis 2005;40(Suppl 6):S409-S413.
33. 33. Coker RJ, Viviani M, Gazzard BG, et al. Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS 1993;7:829-835. (Pubitemid 23212449)
34. Hamill R, Sobel J, El-Sadr W, et al. Randomized double-blind trial of ambisome and amphotericin B in acute cryptococcal meningitis in AIDS patients [abstract 1161]. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1999.
35. 35. Larsen RA, Bozzette SA, Jones BE, et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994; 19:741-745. (Pubitemid 24301152)
36. Mayanja-Kizza H, Oishi K, Mitarai S, et al. Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clin Infect Dis 1998;26:1362-1366. (Pubitemid 28270166)
37. 37. Milefchik E, Leal MA, Haubrich R, et al. Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis. Med Mycol 2008;46:393-395. (Pubitemid 351552497)
38. Pappas PG. Fluconazole plus Amphotericin B vs. Amphotericin B alone for primary treatment of AIDS-associated cryptococcal meningitis: results of a phase II trial [abstract M626]. In: Program and abstracts of the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2007.
39. Larsen RA, Leal MA, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial. Ann Intern Med 1990;113:183-187.
40. 40. Menichetti F, Fiorio M, Tosti A, et al. High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996;22:838-840. (Pubitemid 26255605)
41. Haubrich RH, Haghighat D, Bozzette SA, et al. High-dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection. The California Collaborative Treatment Group. J Infect Dis 1994;170:238-242.
42. Denning DW, Tucker RM, Hanson LH, et al. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch Intern Med 1989; 149:2301-2308.
43. de Gans J, Portegies P, Tiessens G, et al. Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis. AIDS 1992;6:185-190.
44. Cuenca-Estrella M, Diaz-Guerra TM, Mellado E, et al. Flucytosine primary resistance in Candida species and Cryptococcus neoformans. Eur J Clin Microbiol Infect Dis 2001;20:276-279.
45. Schwarz P, Dromer F, Lortholary O, et al. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis. Antimicrob Agents Chemother 2006; 50:113-120.
46. 46. Schwarz P, Janbon G, Dromer F, et. al. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans. Antimicrob Agents Chemother 2007; 51: 383-385. (Pubitemid 46047737)
47. 47. Dannaoui E, Abdul M, Arpin M, et al. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. Antimicrob Agents Chemother 2006;50:2464-2470. (Pubitemid 43993187)
48. 48. Aller AI, Martin-Mazuelos E, Lozano F, et al. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob Agents Chemother 2000;44:1544-1548. (Pubitemid 30340792)
49. Witt MD, Lewis RJ, Larsen RA, et al. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. Clin Infect Dis 1996;22:322-328.
50. 50. Bicanic T. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis 2006; 43:1069-1073. (Pubitemid 44631110)
51. Drew RH, Perfect JR. Flucytosine. In: Yu V, Weber R, Raoult D, eds. Antimicrobial therapy and vaccines. New York: Apple Trees Productions, 1997:656-657.
52. Bozzette SA, Larsen RA, Chiu J, et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med 1991;324:580-584.
53. Powderly WG, Saag MS, Cloud GA, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med 1992;326:793-798.
54. Saag MS, Cloud GA, Graybill JR, et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1999;28:291-296.
55. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS ONE 2009;4:e5575.
56. Sungkanuparph S, Filler SG, Chetchotisakd P, et al. Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study. Clin Infect Dis 2009;49:931-934.
57. Mussini C, Pezzotti P, Miro JM, et al. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. Clin Infect Dis 2004;38:565-571. (Pubitemid 38250968)
58. 58. Vibhagool A, Sungkanuparph S, Mootsikapun P, et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Clin Infect Dis 2003;36:1329-1331. (Pubitemid 36629945)
59. Aberg JA, Price RW, Heeren DM, et al. A pilot study of the discontinuation of antifungal therapy for disseminated cryptococcal disease in patients with acquired immunodeficiency syndrome, following immunologic response to antiretroviral therapy. J Infect Dis 2002; 185: 1179-1182.
60. 60. Martinez E, Garcia-Viejo MA, Marcos MA, et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients responding to highly active antiretroviral therapy. AIDS 2000; 14:2615-2617. (Pubitemid 30840058)
61. 61. Rollot F, Bossi P, Tubiana R, et al. Discontinuation of secondary prophylaxis against cryptococcosis in patients with AIDS receiving highly active antiretroviral therapy. AIDS 2001; 15:1448-1449. (Pubitemid 32662301)
62. 62. Tassie JM, Pepper L, Fogg C, et al. Systematic screening of cryptococcal antigenemia in HIV-positive adults in Uganda. J Acquir Immune Defic Syndr 2003;33:411-412. (Pubitemid 36859071)
63. 63. Nelson MR, Bower M, Smith D, et al. The value of serum cryptococcal antigen in the diagnosis of cryptococcal infection in patients infected with the human immunodeficiency virus. J Infect 1990;21:175-181. (Pubitemid 20329685)
64. 64. Desmet P, Kayembe KD, De Vroey C. The value of cryptococcal serum antigen screening among HIV-positive/AIDS patients in Kinshasa, Zaire. AIDS 1989;3:77-78. (Pubitemid 19073455)
65. 65. Liechty CA, Solberg P, Were W, et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health 2007; 12:929-935. (Pubitemid 47245826)
66. 66. Micol R, Lortholary O, Sar B, et al. Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J Acquir Immune Defic Syndr 2007; 45: 555-559. (Pubitemid 47294928)
67. 67. Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005; 19:399-406. (Pubitemid 40446186)
68. Powderly WG, Finkelstein D, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 1995;332:700-705.
69. McKinsey DS, Wheat LJ, Cloud GA, et al. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1999;28:1049-1056.
70. Jarvis JN, Lawn SD, Vogt M, et al. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 2009;48:856-862.
71. Husain S, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis 2001;7:375-381.
72. 72. Vilchez RA, Fung J, Kusne S. Cryptococcosis in organ transplant recipients: an overview. Am J Transplant 2002; 2:575-580. (Pubitemid 36306848)
73. Singh N, Alexander BD, Lortholary O, et al. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis 2007; 195:756-764.
74. Shaariah W, Morad Z, Suleiman AB. Cryptococcosis in renal transplant recipients. Transplant Proc 1992;24:1898-1899.
75. Singh N, Lortholary O, Alexander BD, et al. Antifungal management practices and evolution of infection in organ transplant recipients with Cryptococcus neoformans infection. Transplantation 2005; 80:1033-1039.
76. 76. Bonner JJ, Carlson T, Fackenthal DL, et al. Complex regulation of the yeast heat shock transcription factor. Mol Biol Cell 2000; 11: 1739-1751. (Pubitemid 30307909)
77. Singh N, Dromer F, Perfect JR, et al. Cryptococcosis in solid organ transplant recipients: current state of the science. Clin Infect Dis 2008;47:1321-1327.
78. 78. Aberg JA, Mundy LM, Powderly WG. Pulmonary cryptococcosis in patients without HIV infection. Chest 1999;115:734-740. (Pubitemid 29129954)
79. 79. Singh N, Alexander BD, Lortholary O, et al. Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen. Clin Infect Dis 2008;46:e12-e18. (Pubitemid 351269182)
80. 80. Singh N, Gayowski T, Marino IR. Successful treatment of disseminated cryptococcosis in a liver transplant recipient with fluconazole and flucytosine, an all oral regimen. Transpl Int 1998;11:63-65. (Pubitemid 28112412)
81. 81. Vilchez RA, Linden P, Lacomis J, et al. Acute respiratory failure associated with pulmonary cryptococcosis in non-AIDS patients. Chest 2001;119:1865-1869. (Pubitemid 32744947)
82. Singh N, Lortholary O, Alexander BD, et al. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis 2005; 40: 1756-1761.
83. 83. Singh N, Perfect JR. Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect Dis 2007;7:395-401. (Pubitemid 46765196)
84. Saha DC, Goldman DL, Shao X, et al. Serologic evidence for reactivation of cryptococcosis in solid-organ transplant recipients. Clin Vaccine Immunol 2007;14:1550-1554.
85. Ecevit IZ, Clancy CJ, Schmalfuss IM, et al. The poor prognosis of central nervous system cryptococcosis among nonimmunosuppressed patients: a call for better disease recognition and evaluation of adjuncts to antifungal therapy. Clin Infect Dis 2006;42:1443-1447.
86. Zonios DI, Falloon J, Huang CY, et al. Cryptococcosis and idiopathic CD4 lymphocytopenia. Medicine (Baltimore) 2007;86:78-92.
87. Rex JH, Larsen RA, Dismukes WE, et al. Catastrophic visual loss due to Cryptococcus neoformans meningitis. Medicine (Baltimore) 1993; 72:207-224.
88. 88. Dromer F, Mathoulin S, Dupont B, et al. Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. French Cryptococcosis Study Group. Clin Infect Dis 1996;22(Suppl 2):S154-S160. (Pubitemid 26256448)
89. Pappas PG, Perfect JR, Cloud GA, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 2001;33:690-699.
90. 90. Pappas PG, Bustamante B, Ticona E, et al. Recombinant interferonγ 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis 2004;189:2185-2191. (Pubitemid 38757190)
91. Bicanic T, Brouwer AE, Meintjes G, et al. Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS 2009; 23:701-706.
92. Pappas PG. Managing cryptococcal meningitis is about handling the pressure. Clin Infect Dis 2005;40:480-482.
93. 93. Charlier C, Dromer F, Leveque C, et al. Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era. PLoS ONE 2008;3:e1950. (Pubitemid 352003414)
94. 94. Woodworth GF, McGirt MJ, Williams MA, et al. The use of ventriculoperitoneal shunts for uncontrollable intracranial hypertension without ventriculomegally secondary to HIV-associated cryptococcal meningitis. Surg Neurol 2005;63:529-531; discussion 531-532. (Pubitemid 40779687)
95. 95. Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis 2000; 30:47-54. (Pubitemid 30067061)
96. Sun HY, Hung CC, Chang SC. Management of cryptococcal meningitis with extremely high intracranial pressure in HIV-infected patients. Clin Infect Dis 2004;38:1790-1792.
97. Newton PN, Thai le H, Tip NQ, et al. A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clin Infect Dis 2002; 35:769-772.
98. Park MK, Hospenthal DR, Bennett JE. Treatment of hydrocephalus secondary to cryptococcal meningitis by use of shunting. Clin Infect Dis 1999;28:629-633.
99. 99. Macsween KF, Bicanic T, Brouwer AE, et al. Lumbar drainage for control of raised cerebrospinal fluid pressure in cryptococcal meningitis: case report and review. J Infect 2005;51:e221-e224. (Pubitemid 41683887)
100. Coplin WM, Avellino AM, Kim DK, et al. Bacterial meningitis associated with lumbar drains: a retrospective cohort study. J Neurol Neurosurg Psychiatry 1999;67:468-473.
101. 101. Lindvall P, AhIm C, Ericsson M, et al. Reducing intracranial pressure may increase survival among patients with bacterial meningitis. Clin Infect Dis 2004;38:384-390. (Pubitemid 38200115)
102. Jenny-Avital ER, Abadi M. Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy. Clin Infect Dis 2002;35:e128-e133.
103. Skiest DJ, Hester LJ, Hardy RD. Cryptococcal immune reconstitution inflammatory syndrome: report of four cases in three patients and review of the literature. J Infect 2005;51:e289-e297.
104. 104. Lortholary O, Fontanet A, Memain N, et al. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 2005;19:1043-1049. (Pubitemid 40961144)
105. Shelburne SA 3rd, Darcourt J, White AC Jr, et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis 2005;40:1049-1052.
106. 106. Lesho E. Evidence base for using corticosteroids to treat HIV-associated immune reconstitution syndrome. Expert Rev Anti Infect Ther 2006;4:469-478. (Pubitemid 43905468)
107. McComsey GA, Whalen CC, Mawhorter SD, et al. Placebo-controlled trial of prednisone in advanced HIV-1 infection. AIDS 2001; 15: 321-327.
108. Speed B, Dunt D. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis 1995;21:28-34; discussion 35-36.
109. Mitchell DH, Sorrell TC, Allworth AM, et al. Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. Clin Infect Dis 1995; 20: 611-616.
110. Chen S, Sorrell T, Nimmo G, et al. Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. Clin Infect Dis 2000;31:499-508.
111. Hospenthal DR, Bennett JE. Persistence of cryptococcomas on neuroimaging. Clin Infect Dis 2000;31:1303-1306.
112. Mitchell DH, Sorrell TC. Pancoast's syndrome due to pulmonary infection with Cryptococcus neoformans variety gattii. Clin Infect Dis 1992;14:1142-1144.
113. Cochius JI, Burns RJ, Willoughby JO. CNS cryptococcosis: unusual aspects. Clin Exp Neurol 1989;26:183-191.
114. Waterston JA, Gilligan BS. Cryptococcal infections of the central nervous system: a ten year experience. Clin Exp Neurol 1987; 23:127-137.
115. Fisher D, Burrow J, Lo D, et al. Cryptococcus neoformans in tropical northern Australia: predominantly variant gattii with good outcomes. Aust N Z J Med 1993;23:678-682.
116. Jenney A, Pandithage K, Fisher DA, et al. Cryptococcus infection in tropical Australia. J Clin Microbiol 2004;42:3865-3868.
117. Brouwer AE, Siddiqui AA, Kester MI, et al. Immune dysfunction in HIV-seronegative, Cryptococcus gattii meningitis. J Infect 2007; 54:e165-e168.
118. Einsiedel L, Gordon DL, Dyer JR. Paradoxical inflammatory reaction during treatment of Cryptococcus neoformans var. gattii meningitis in an HIV-seronegative woman. Clin Infect Dis 2004;39:e78-e82.
119. Blackie JD, Danta G, Sorrell T, et al. Ophthalmological complications of cryptococcal meningitis. Clin Exp Neurol 1985;21:263-270.
120. 120. Visnegarwala F, Graviss EA, Lacke CE, et al. Acute respiratory failure associated with cryptococcosis in patients with AIDS: analysis of predictive factors. Clin Infect Dis 1998;27:1231-1237. (Pubitemid 29242476)
121. Meyohas MC, Roux P, Bollens D, et al. Pulmonary cryptococcosis: localized and disseminated infections in 27 patients with AIDS. Clin Infect Dis 1995;21:628-633.
122. 122. Kerkering TM, Duma RJ, Shadomy S. The evolution of pulmonary cryptococcosis: clinical implications from a study of 41 patients with and without compromising host factors. Ann Intern Med 1981; 94: 611-616. (Pubitemid 11112636)
123. Beeson PB. Cryptococcic meningitis of nearly sixteen years' duration. AMA Arch Intern Med 1952;89:797-801.
124. Nadrous HF, Antonios VS, Terrell CL, et al. Pulmonary cryptococcosis in nonimmunocompromised patients. Chest 2003;124:2143-2147.
125. 125. Yamaguchi H, Ikemoto H, Watanabe K, et al. Fluconazole monotherapy for cryptococcosis in non-AIDS patients. Eur J Clin Microbiol Infect Dis 1996; 15:787-792. (Pubitemid 26386120)
126. Nunez M, Peacock JE Jr, Chin R Jr. Pulmonary cryptococcosis in the immunocompetent host. Therapy with oral fluconazole: a report of four cases and a review of the literature. Chest 2000;118:527-534.
127. Yao Z, Liao W, Chen R. Management of cryptococcosis in non-HIV-related patients. Med Mycol 2005;43:245-251.
128. Raad, II, Graybill JR, Bustamante AB, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006;42:1726-1734.
129. Baddley JW, Perfect JR, Oster RA, et al. Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease. Eur J Clin Microbiol Infect Dis 2008;27:937-943.
130. 130. Igai H, Gotoh M, Yokomise H. Computed tomography (CT) and positron emission tomography with [18F]fluoro-2-deoxy-D-glucose (FDG-PET) images of pulmonary cryptococcosis mimicking lung cancer. Eur J Cardiothorac Surg 2006;30:837-839. (Pubitemid 44738620)
131. Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS-100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 1995;8:515-548.
132. 132. Neuville S, Dromer F, Morin O, et al. Primary cutaneous cryptococcosis: a distinct clinical entity. Clin Infect Dis 2003; 36:337-347. (Pubitemid 36169670)
133. 133. Behrman RE, Masci JR, Nicholas P. Cryptococcal skeletal infections: case report and review. Rev Infect Dis 1990;12:181-190. (Pubitemid 20118644)
134. Larsen RA, Bozzette S, McCutchan JA, et al. Persistent Cryptococcus neoformans infection of the prostate after successful treatment of meningitis. California Collaborative Treatment Group. Ann Intern Med 1989;111:125-128.
135. Ely EW, Peacock JE Jr, Haponik EF, et al. Cryptococcal pneumonia complicating pregnancy. Medicine (Baltimore) 1998;77:153-167.
136. Philpot CR, Lo D. Cryptococcal meningitis in pregnancy. Med J Aust 1972;2:1005-1007.
137. 137. Dean JL, Wolf JE, Ranzini AC, et al. Use of amphotericin B during pregnancy: case report and review. Clin Infect Dis 1994; 18:364-368. (Pubitemid 24086306)
138. Ismail MA, Lerner SA. Disseminated blastomycosis in a pregnant woman: review of amphotericin B usage during pregnancy. Am Rev Respir Dis 1982; 126:350-353.
139. McCoy MJ, Ellenberg JF, Killam AP. Coccidioidomycosis complicating pregnancy. Am J Obstet Gynecol 1980; 137:739-740.
140. Spinello IM, Johnson RH, Baqi S. Coccidioidomycosis and pregnancy: a review. Ann N Y Acad Sci 2007; 1111:358-364.
141. King CT, Rogers PD, Cleary JD, et al. Antifungal therapy during pregnancy. Clin Infect Dis 1998;27:1151-1160.
142. Tiboni GM. Second branchial arch anomalies induced by fluconazole, a bis-triazole antifungal agent, in cultured mouse embryos. Res Commun Chem Pathol Pharmacol 1993;79:381-384.
143. 143. Pursley TJ, Blomquist IK, Abraham J, et al. Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis 1996; 22:336-340. (Pubitemid 26056165)
144. 144. Costeas PA, Koumouli A, Giantsiou-Kyriakou A, et al. Th2/Th3 cytokine genotypes are associated with pregnancy loss. Hum Immunol 2004;65:135-141. (Pubitemid 38224139)
145. Annapureddy SR, Masterson SW, David HG, et al. Post partum osteomyelitis due to Cryptococcus neoformans. Scand J Infect Dis 2007; 39:354-356.
146. 146. Singh N, Perfect JR. Immune reconstitution syndrome and exacerbation of infections after pregnancy. Clin Infect Dis 2007;45:1192-1199. (Pubitemid 47580319)
147. Abadi J, Nachman S, Kressel AB, et al. Cryptococcosis in children with AIDS. Clin Infect Dis 1999;28:309-313.
148. 148. Gonzalez CE, Shetty D, Lewis LL, et al. Cryptococcosis in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1996;15:796-800. (Pubitemid 26304455)
149. 149. McCarthy KM, Morgan J, Wannemuehler KA, et al. Population-based surveillance for cryptococcosis in an antiretroviral-naive South African province with a high HIV seroprevalence. AIDS 2006; 20:2199-2206. (Pubitemid 44684711)
150. Likasitwattanakul S, Poneprasert B, Sirisanthana V. Cryptococcosis in HIV-infected children. Southeast Asian J Trop Med Public Health 2004;35:935-939.
151. Sirinavin S, Intusoma U, Tuntirungsee S. Mother-to-child transmission of Cryptococcus neoformans. Pediatr Infect Dis J 2004; 23:278-279.
152. Kaur R, Mittal N, Rawat D, et al. Cryptococcal meningitis in a neonate. Scand J Infect Dis 2002;34:542-543.
153. 153. Tuerlinckx D, Bodart E, Garrino MG, et al. Cutaneous lesions of disseminated cryptococcosis as the presenting manifestation of human immunodeficiency virus infection in a twenty-two-month-old child. Pediatr Infect Dis J 2001; 20:463-464. (Pubitemid 32294768)
154. Chaudhary MW, Sardana K, Kumar P, et al. Disseminated infection with Cryptococcus neoformans var neoformans in an 8 years immunocompetent girl. Indian J Pediatr 2005; 72:85.
155. Grant E, Junker A. Nine-year-old girl with lymphangiectasia and chest pain. Pediatr Infect Dis J 2005; 24:659, 663-664.
156. Manfredi R, Coronado OV, Mastroianni A, et al. Liposomal amphotericin B and recombinant human granulocyte-macrophage colonystimulating factor (rHuGM-CSF) in the treatment of paediatric AIDSrelated cryptococcosis. Int. J STD AIDS 1997;8:406-408.
157. Athanassiadou F, Tragiannidis A, Papageorgiou T, et al. Fungal brain abscesses in leukemia. Indian Pediatr 2006;43:991-994.
158. Wiley JM, Seibel NL, Walsh TJ. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections. Pediatr Infect Dis J 2005;24:167-174.
159. Smego RA, Jr., Perfect JR, Durack DT. Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis. Rev Infect Dis 1984;6:791-801.
160. Stamm AM, Diasio RB, Dismukes WE, et al. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med 1987;83:236-242.
161. 161. Soltani M, Tobin CM, Bowker KE, et al. Evidence of excessive concentrations of 5-flucytosine in children aged below 12 years: a 12-year review of serum concentrations from a UK clinical assay reference laboratory. Int J Antimicrob Agents 2006; 28:574-577. (Pubitemid 44779176)
162. Lee JW, Seibel NL, Amantea M, et al. Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. J Pediatr 1992; 120:987-993.
163. Seay RE, Larson TA, Toscano JP, et al. Pharmacokinetics of fluconazole in immune-compromised children with leukemia or other hematologic diseases. Pharmacotherapy 1995; 15:52-58.
164. 164. Negroni R, Helou SH, Lopez Daneri G, et al. Successful discontinuation of antifungal secondary prophylaxis in AIDS-related cryptococcosis [in Spanish]. Rev Argent Microbiol 2004;36:113-117. (Pubitemid 39482198)
165. Sheng WH, Hung CC, Chen MY, et al. Successful discontinuation of fluconazole as secondary prophylaxis for cryptococcosis in AIDS patients responding to highly active antiretroviral therapy. Int J STD AIDS 2002; 13:702-705.
166. 166. Nwokolo NC, Fisher M, Gazzard BG, et al. Cessation of secondary prophylaxis in patients with cryptococcosis. AIDS 2001; 15:1438-1439. (Pubitemid 32662297)
167. 167. Puthanakit T, Oberdorfer P, Akarathum N, et al. Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected Thai children. Pediatr Infect Dis J 2006;25:53-58. (Pubitemid 43361477)
168. Andes D. Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin North Am 2006;20:679-697.
169. de Lalla F, Pellizzer G, Vaglia A, et al. Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of rdatively high doses administered over a relatively short period. Clin Infect Dis 1995;20:263-266.
170. 170. Pitisuttithum P, Tansuphasawadikul S, Simpson AJ, et al. A prospective study of AIDS-associated cryptococcal meningitis in Thailand treated with high-dose amphotericin B. J Infect 2001;43:226-233. (Pubitemid 34100463)
171. 171. Tansuphaswadikul S, Maek-a-Nantawat W, Phonrat B, et al. Comparison of one week with two week regimens of amphotericin B both followed by fluconazole in the treatment of cryptococcal meningitis among AIDS patients. J Med Assoc Thai 2006;89:1677-1685. (Pubitemid 44747540)
172. 172. Mwaba P, Mwansa J, Chintu C, et al. Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgrad Med J 2001;77:769-773. (Pubitemid 33116512)
173. 173. Schaars CF, Meintjes GA, Morroni C, et al. Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole. BMC Infect. Dis 2006; 6:118. (Pubitemid 46277110)
174. 174. Kartalija M, Kaye K, Tureen JH, et al. Treatment of experimental cryptococcal meningitis with fluconazole: impact of dose and addition of flucytosine on mycologic and pathophysiologic outcome. J Infect Dis 1996;173:1216-1221. (Pubitemid 26251466)
175. Anaissie EJ, Kontoyiannis DP, Huls C, et al. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. J Infect Dis 1995;172:599-602.
176. Appelbaum E, Shtokalko S. Cryptococcus meningitis arrested with amphotericin B. Ann Intern Med 1957;47:346-351.
177. Longley N, Muzoora C, Taseera K, et al. Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis 2008;47:1556-1561.
178. 178. Manosuthi W, Athichathanabadi C, Uttayamakul S, et al. Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole. BMC Infect Dis 2007; 7:14. (Pubitemid 46455921)
179. Kappelhoff BS, van Leth F, Robinson PA, et al. Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir Ther 2005; 10:489-498.
180. Barrett JS, Joshi AS, Chai M, et al. Population pharmacokinetic metaanalysis with efavirenz. Int J Clin Pharmacol Ther 2002;40:507-519.
181. Allendoerfer R, Marquis AJ, Rinaldi MG, et al. Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis. Antimicrob Agents Chemother 1991;35:726-729.
182. 182. Ding JC, Bauer M, Diamond DM, et al. Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis. Antimicrob Agents Chemother 1997;41:1589-1593. (Pubitemid 27289693)
183. Laurenson IF, Trevett AJ, Lalloo DG, et al. Meningitis caused by Cryptococcus neoformans var. gattii and var. neoformans in Papua New Guinea. Trans R Soc Trop Med Hyg 1996;90:57-60.
184. 184. Taelman H, Bogaerts J, Batungwanayo J, et al. Failure of the cryptococcal serum antigen test to detect primary pulmonary cryptococcosis in patients infected with human immunodeficiency virus. Clin Infect Dis 1994;18:119-120. (Pubitemid 24025933)
185. Morgan J, McCarthy KM, Gould S, et al. Cryptococcus gattii infection: characteristics and epidemiology of cases identified in a South African province with high HIV seroprevalence, 2002-2004. Clin Infect Dis 2006;43:1077-1080.
186. Thompson GR 3rd, Wiederhold NP, Fothergill AW, et al. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother 2009; 53: 309-311.
187. Tay ST, Tanty Haryanty T, Ng KP, et al. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs. Mycoses 2006; 49:324-330.
188. Lalloo D, Fisher D, Naraqi S, et al. Cryptococcal meningitis (C. neoformans var. gattii) leading to blindness in previously healthy Melanesian adults in Papua New Guinea. Q J Med 1994;87:343-349.
189. Morera-Lopez Y, Torres-Rodriguez JM, Jimenez-Cabello T, et al. Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole. Med Mycol 2005; 43:505-510.
190. West SK, Byrnes E, Mustad S, et al. Emergence of Cryptococcus gattii in the Pacific Northwest United States [abstract M1849]. In: Program and abstracts of the 48th Interscience Conference Antimicrobial Agents Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2008.
191. 191. Seaton RA, Verma N, Naraqi S, et al. Visual loss in immunocompetent patients with Cryptococcus neoformans var. gattii meningitis. Trans R Soc Trop Med Hyg 1997;91:44-49. (Pubitemid 27095499)